おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Aevi Genomic Medicine
company
About
Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies.
- 11 - 50
Highlights
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $28M
- Industries
- Biopharma,Biotechnology,Health Care,Life Science
- Founded date
- Jan 1, 2000
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies. It is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies.Driven by a commitment to patients with pediatric onset life-altering diseases, the company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics at The Children's Hospital of Philadelphia.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$28M
Aevi Genomic Medicine has raised a total of
$28M
in funding over 2 rounds. Their latest funding was raised on
Oct 17, 2017 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 17, 2017 | Post-IPO Equity | $28M | 1 |
The Children's Hospital of Philadelphia
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Aevi Genomic Medicine is funded by 1 investors.
The Children's Hospital of Philadelphia
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
The Children's Hospital of Philadelphia
|
Yes | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
